C
CancerIQ
CancerIQ harnesses big data to accelerate personalized cancer care
About CancerIQ
CancerIQ operates within the specialized field of precision cancer prevention, offering a platform designed to assist healthcare providers in identifying, evaluating, and managing patients who are at a heightened risk for hereditary cancer. The company was co-founded in 2013 by Olufunmilayo I. Olopade, MD, a distinguished oncologist and expert in cancer genetics, and her daughter, Feyi Olopade Ayodele, who serves as the CEO. The inception of the company is rooted in Dr. Olopade's extensive clinical and research experience at the University of Chicago, where she recognized the critical gap between genetic discoveries and their practical application in patient care.
Feyi Olopade Ayodele brings a complementary background in business and finance to the company. Holding an MBA from The Wharton School, her expertise has been instrumental in navigating the complex healthcare market and scaling the company's operations. This mother-daughter partnership combines deep clinical and genetic knowledge with strategic business acumen, directly addressing the challenge of integrating genetic risk assessment into routine clinical workflow.
The company's core offering is a software platform that automates the process of identifying at-risk patients through screening questionnaires, pedigree analysis, and the integration of genetic test results. This system streamlines what is traditionally a time-consuming and manual process, allowing clinicians to more efficiently determine who may benefit from genetic counseling and testing. The platform serves a diverse client base, including hospitals, cancer centers, and women's health clinics. CancerIQ's business model is primarily based on a subscription-based software-as-a-service (SaaS) model, where healthcare organizations pay for access to the platform to manage their high-risk patient populations effectively.
By providing tools that support early detection and preventative care, CancerIQ aims to shift the paradigm from reactive cancer treatment to proactive cancer risk management. The platform facilitates guideline-based care, helping providers to create personalized care plans for high-risk individuals, which may include increased surveillance, risk-reducing medications, or preventative surgeries. The company has secured multiple rounds of funding, including a notable $14 million Series B financing round, to expand its technology and market reach.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 32
- Open positions
- None listed
- Dealroom signal
- 68.6/100
- Industry
- Health
- Sector
- Testing, Risk Management, Oncology, DNA, Genetics and genomics, Patient Care, Spinout, Genome Engineering, medical testing, DT and LS
- Technology
- Big Data, Deep Tech
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VC✓Equity / VC | Aug 2024 | $0 | — | Decathlon Capital Partners | ↗ |
| SERIES B✓Equity / VC | Mar 2022 | $14M | $56M | Merck Global Health Innovation Fund · HealthX Ventures · Amgen Ventures · OSF Ventures | ↗ |
Growth signals
Latest recorded traffic for CancerIQ is 22K monthly website visits, down 18.5% over the last three months. CancerIQ's team declined 8.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
CancerIQ in the Chicago ecosystem
The CancerIQ office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A5 investors entered at this stage
Impact Engine
HealthX Ventures
Merck Global Health Innovation Fund
Amgen Ventures
OSF Ventures
Series B and later1 investor entered at this stage
- DPDecathlon Capital Partners
Other known investors6 additional known investors
The University of Chicago
76 Forward
Lightbank
McKesson Ventures
OSF
Rock Health Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CancerIQ on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CancerIQ’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










